Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial
British Journal of Clinical Pharmacology · 17.11.2026
DOI: 10.1002/bcp.70912 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 17.11.2026. Verfasst von Damilola Olabode und 7 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Aims
The phase 3 ECHO trial demonstrated superior progression‐free survival (PFS) with acalabrutinib plus bendamustine‐rituximab (BR) versus placebo plus BR in treatment‐naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP‐5862 (active metabolite) when administered with BR and evaluates exposure–response (efficacy/safety) relationships based on ECHO data.
Methods
In ECHO, patients aged ≥65 years with TN MCL received BR plus acalabrutinib or placebo. Acalabrutinib (100 mg twice daily) or placebo was administered at study start until progressive disease or unacceptable toxicity. A pooled population PK analysis dataset included 975 patients for acalabrutinib and 580 patients for ACP‐5862 from ECHO plus 10 clinical trials. Exposure–response analyses examined associations between exposure and PFS, best overall response (BOR), and adverse events (AEs) from ECHO.
Results
Population PK analysis showed that demographics (age, body weight, sex, ethnicity, race) and other intrinsic factors (mild or moderate renal impairment; mild or moderate hepatic impairment) had no meaningful effect on acalabrutinib/ACP‐5862 exposure. No impact of co‐administration with BR was observed on PK exposure. Exposure–efficacy analyses of ECHO data showed a flat relationship between acalabrutinib/ACP‐5862 exposure and PFS and BOR. Exposure–safety analyses of ECHO data showed no clinically meaningful correlation between acalabrutinib/ACP‐5862 exposure and selected safety outcomes (grade ≥3 AEs and events of clinical interest, AEs leading to dose modifications).
Conclusion
This analysis supports a fixed 100 mg twice daily acalabrutinib dose, in combination with BR, as well‐tolerated and efficacious in treatment of patients with TN MCL.
Förderung
- AstraZeneca
Zitieren
APA
Olabode, D., Zhou, D., Siddiki, N., Yang, J., Vishwanathan, K., Calvo, R., Rule, S., & Sharma, S. (2026). Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70912
Vancouver
Olabode D, Zhou D, Siddiki N, Yang J, Vishwanathan K, Calvo R, et al. Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70912
BibTeX
@article{Olabode2026,
author = {Olabode, Damilola and Zhou, Diansong and Siddiki, Nurahamid and Yang, Jincheng and Vishwanathan, Karthick and Calvo, Roser and Rule, Simon and Sharma, Shringi},
title = {Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70912}
}
EUVIMED